The abstract is read at the publisher; the summary is JClub's.
Cisplatin plus gemcitabine in the adjuvant setting for resected biliary tract cancer did not statistically improve disease-free survival versus capecitabine (25.7 vs 17.9 months).
- Why it matters: Even after curative resection and adjuvant capecitabine, about half of biliary tract cancer patients recur or die within 2 years, leaving an unmet need for better adjuvant therapy.
- What they did: In ACTICCA-1, a randomized phase III trial across 67 sites in 8 countries (Sep 2017–Jan 2023), 591 patients received cisplatin/gemcitabine or capecitabine for 24 weeks; DFS was the primary endpoint.
- The result: CisGem increased RMST DFS by 2.6 months on average (95% CI 0.6–4.68; P = 0.011) but did not yield a significant OS benefit (RMST P = 0.076), with higher severe toxicity (130 vs 113).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.